← Back to Home

Cholesterol-Lowering Treatment Crosses the Injection Barrier: U.S. Approves First Oral PCSK9 Inhibitor

Once-daily Lipfendra can substantially reduce low-density lipoprotein cholesterol, offering a new non-injectable option for patients with high cholesterol; however, whether the numerical improvement will translate into fewer heart attacks and strokes remains to be answered by a large trial.

By SURL BioNews

For years, cholesterol-lowering drugs targeting PCSK9 have been able to significantly reduce low-density lipoprotein cholesterol (LDL-C), commonly known as “bad cholesterol,” but have largely relied on injections. The U.S. Food and Drug Administration (FDA) has now approved Merck’s Lipfendra (generic name: enlicitide), bringing this treatment mechanism into the oral era for the first time and adding an option for patients whose cholesterol remains elevated after existing therapies.

Lipfendra is a 20 mg, once-daily cyclic peptide drug indicated for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, and is to be used alongside diet and exercise. It binds to PCSK9, preventing it from interfering with LDL receptors on the surface of liver cells. When more receptors are preserved, LDL can be cleared from the blood more effectively.

The approval was based on two randomized, double-blind, placebo-controlled trials involving a total of 3,207 adults receiving maximally tolerated statin therapy. The larger CORALreef Lipids trial included 2,904 participants, while the CORALreef HeFH trial enrolled 303 patients with heterozygous familial hypercholesterolemia. After 24 weeks of treatment, mean LDL-C levels in the Lipfendra groups were reduced by 56% and 59%, respectively, compared with the placebo groups.

Other lipid measures also improved. According to trial data, non-high-density lipoprotein cholesterol fell by 54% and 52%, respectively, in the two studies, while apolipoprotein B declined by 50% and 48%. One-year data showed that the LDL-C-lowering effect was largely sustained, with only slight attenuation. These results demonstrate that the drug has stable lipid-lowering activity, but they cannot be directly equated with a reduction in the risk of myocardial infarction, stroke, or death.

The convenience of treatment also comes with conditions: the tablet must be taken in the morning on an empty stomach, followed by a wait of at least 30 minutes before eating. Reported adverse reactions include diarrhea and dizziness. In the CORALreef HeFH trial, diarrhea occurred in 7% of participants, compared with 2% in the placebo group, while dizziness occurred in 9% and 4%, respectively. Individual adverse-effect data come from a specific trial population and may not fully represent what will occur with broader use in the future.

The largest evidence gap at present is whether Lipfendra can reduce cardiovascular disease and death. This clinical benefit has not yet been established. The ongoing CORALreef Outcomes trial has enrolled more than 14,500 people and will assess whether the magnitude of lipid reduction can genuinely translate into fewer major cardiovascular events. Until the results are available, this approval primarily changes the method of administration and treatment accessibility, rather than establishing a definitive conclusion about long-term outcomes.

References

  1. U.S. Food and Drug Administration
  2. Merck
  3. Associated Press
  4. American College of Cardiology
  5. Pharmacy Times